Diagnostic News and Research

RSS

FDA clears ZOLL's new Propaq MD Monitor/Defibrillator

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® MD Monitor/Defibrillator that was developed specifically to meet the special needs of military customers and air medical operations worldwide. Development of this product was a joint undertaking between the Department of Defense and a cooperative arrangement between Welch Allyn and ZOLL.

30 Jul 2010

Despite all advancements in melanoma diagnosis, rapid treatment remains critical: Report

Twenty-five years after publishing the mnemonic "ABCD" to facilitate the early diagnosis of melanoma, the group who came up with that moniker says early detection remains a key factor in lowering mortality from malignant melanoma. Darrell S. Rigel, M.D. and colleagues from the Ronald O. Perelman Department of Dermatology at New York University School of Medicine say that, despite all of the advances in melanoma diagnosis, timely recognition, detection, and rapid treatment of melanoma remain critical.

30 Jul 2010

NewCardio enters new line of credit with existing shareholders

NewCardio, Inc., a cardiac diagnostic technology provider, today announced that it has entered into a new line of credit with three of its existing shareholders, one of which is represented on the Board of Directors, to strengthen its financial position. This will allow the company further time to fully commercialize its lead solution, QTinno™.

30 Jul 2010

Graymark Healthcare adds two new sleep centers in Texas, Nebraska

Graymark Healthcare announced that it has added two new sleep centers in Texas and Nebraska with the signing of agreements to provide on-site services to Goodall-Witcher Medical Center in Central Texas and Henderson Community Hospital in Nebraska. These agreements continue to execute on Graymark's strategy to expand the availability of sleep medicine in rural communities that otherwise might not have access to comprehensive sleep care.

30 Jul 2010

Surgeons continue to advance minimally-invasive surgery for kidney cancer patients

Surgeons at the University of California, San Diego School of Medicine continue to advance minimally-invasive surgery for cancer patients by reducing the number of abdominal incisions from approximately six to a single small incision.

30 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

30 Jul 2010

AdvanDx's 90 minutes protocol for Yeast Traffic Light PNA FISH test receives FDA 510(k) clearance

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its Yeast Traffic Light® PNA FISH® test. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

30 Jul 2010

Researchers identify genetic mutation for Uner Tan Syndrome

A team of researchers from leading universities in Turkey and the United States have reported that they have identified the genetic mutation responsible for the Uner Tan Syndrome (UTS) using advanced genetic capture and sequencing technologies from Roche. The combined genomic technologies enabled the team of scientists to identify the causative mutation of this debilitating disease after years of mystery.

30 Jul 2010

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Medtronic, Inc. today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry's first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation, or neurostimulation, to improve clinical signs and symptoms of heart failure.

30 Jul 2010

Respiratory symptoms are accurate indicators of influenza infection

New research shows that individuals with mild H1N1 infection may go undetected using standard diagnostic criteria, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, (APIC). The study concludes that coughing or other respiratory symptoms are more accurate in determining influenza infection than presence of a fever.

30 Jul 2010

Fecal occult blood tests make cost effective alternatives in colorectal cancer screening

While colonoscopies are the most accurate method for the early detection of colorectal cancers, screening with fecal occult blood tests results in more efficient use of limited budgets, according to a new study by researchers at RTI International.

30 Jul 2010

SeraCare Life Sciences launches new product to diagnose HIV

SeraCare Life Sciences, Inc. today announced that the Company has launched a set of new products in its diagnostic controls and panels portfolio—the SeraCare HIV-1 Seroconversion Panels. Each of the six panels consists of a set of undiluted plasma samples from a single plasma donor collected over a period of time during the development of detectable specific antibodies to HIV in the blood, or seroconversion, and is highly characterized with enhanced product information.

30 Jul 2010

Cardiac Science reports revenues of $36.1 million for second-quarter 2010

Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today announced its financial results for the second quarter of 2010.

30 Jul 2010

Quidel second-quarter total revenues increase 1.6% to $25.0 million

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today financial results for the second quarter ended June 30, 2010.

30 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

Ortho Kinematics: 23 patients enrolled in KineGraph VMA clinical study

Ortho Kinematics, a privately held spine diagnostics company focused on revolutionizing spine motion analysis, announced today that it has begun a multi-site clinical study of the KineGraph VMA™, and that the initial 23 patients have been enrolled. The study will help determine which types of patients are best evaluated with KineGraph VMA testing. The KineGraph VMA is designed to provide functional diagnostic information to spine surgeons to be used in conjunction with MRI and plain X-rays.

29 Jul 2010

BD third-quarter revenues increase 3.2% to $1.878 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.878 billion for the third fiscal quarter ended June 30, 2010, representing an increase of 3.2 percent from the prior-year period, or 3.9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 29 Jul 2010

Merit Medical second-quarter revenues increase 16% to $74.9 million

Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and gastroenterology, today announced record revenues of $74.9 million for the quarter ended June 30, 2010, an increase of 16% over revenues of $64.8 million for the quarter ended June 30, 2009. Revenues for the six-month period ended June 30, 2010 were a record $142.4 million, compared with $123.2 million for the corresponding period in 2009, a gain of 16%.

29 Jul 2010

Quest Diagnostics' Fragile X Syndrome test receives New York State health department approval

An accurate, faster testing option to identify female carriers and other patients with genetic abnormalities that cause Fragile X Syndrome is now available to physicians in all fifty states with the recent approval in New York. Fragile X is the leading cause of inherited mental retardation and the most common known single gene cause of autism.

From Quest Diagnostics 29 Jul 2010

Mapping NTDs is critical for controlling, treating diseases

Mapping neglected tropical diseases (NTDs) is vital for efforts to control and treat diseases, write the authors of an editorial published Tuesday in PLoS Neglected Tropical Diseases, ANI/Sindh Today reports (7/28).

29 Jul 2010